Retinitis Pigmentosa: Competitive Landscape to 2026
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Retinitis pigmentosa (RP) encompasses a heterogeneous group of rare, inherited retinal disorders characterized by diffuse progressive dysfunction of primarily rod photoreceptors, with subsequent degeneration of cone photoreceptors, and retinal pigment epithelium. Primary symptoms include night blindness and progressive vision field loss, eventually leading to blindness.
This report provides an assessment of the pipeline, clinical, and commercial landscape of RP. Overall, GlobalData expects new drug approvals, including gene therapy, stem cell therapy, and small molecule to drive RP market growth over the next decade (2016–2026).
Scope
GlobalData’s Retinitis Pigmentosa: Competitive Landscape to 2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the slide deck include:
• Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by molecule type
• Clinical Trials Assessment—trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
• Commercial Assessment—leading marketed products, current and future players
• Competitive Landscape Analysis—key market events (2016–2026)
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global RP market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RP market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Novartis
Neurotech Pharmaceuticals
Novelion Therapeutics
jCyte
Ocugen
Innovations In Sight
Horama
Neurotech Pharmaceuticals
Allergan
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.